Prajwal Agale

The Recombinant Coagulation Factors Market is expected to reach $26.29 billion by 2031, growing at a CAGR of 8.6% from 2024 to 2031. Unlike plasma-derived factors, recombinant coagulation factors are produced through recombinant DNA technology, which minimizes the risk of blood-borne infections such as hepatitis C and HIV. This advanced production method significantly enhances safety, making recombinant factors the preferred choice for treating bleeding disorders like hemophilia.